Last Updated: 2026

BioXyTran

Summary

Summary

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

History

BioXyTran was founded in 2006 to increase understanding of the immune system and develop new drugs for cancer and infectious diseases. Since then, the company has grown to become a leader in the field, working with some of the world’s leading pharmaceutical companies and academic institutions.

Mission

To discover and develop life-saving and life-enhancing drugs through innovation and collaboration.

Vision

To be a leader in the development of therapeutic treatments to fight life-threatening diseases worldwide.

References

https://finance.yahoo.com/quote/BIXT/profile?p=BIXT

https://www.crunchbase.com/organization/bioxytran-inc

https://companiesmarketcap.com/

https://www.bioxytraninc.com

Leadership team

Dr. David Platt Ph.D. (Chairman, CEO & Pres)

Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, CMA, CPA, M.B.A. (CFO, Treasurer & Sec.)